NAV

Thyrotropin alfa

Identification

Summary

Thyrotropin alfa is a recombinant form of thyroid stimulating hormone used in diagnostic testing for thyroid cancer and alongside radioactive agents to destroy thyroid tissue.

Brand Names
Thyrogen
Generic Name
Thyrotropin alfa
DrugBank Accession Number
DB00024
Background

Thyrotropin alfa is a recombinant form of thyroid stimulating hormone used in performing certain tests in patients who have or have had thyroid cancer. It is also used along with a radioactive agent to destroy remaining thyroid tissue in certain patients who have had their thyroid gland removed because of thyroid cancer. It is a heterodimeric glycoprotein comprised of two non-covalently linked subunits, an alpha subunit of 92 amino acid residues containing two N-linked glycosylation sites and a beta subunit of 112 residues containing one N-linked glycosylation site. The alpha subunit of thyrotropin alfa, which is the effector region responsible for the stimulation of adenylate cyclase, displays close structural similarity with the alpha subunit of human chorionic gonadotropin (hCG), luteinizing hormone (LH), and follicle-stimulating hormone (FSH). The beta subunit (TSHB) bestows its receptor specificity due to the uniqueness to TSH. The amino acid sequence of thyrotropin alfa is identical to that of human pituitary thyroid stimulating hormone.

Type
Biotech
Groups
Approved, Vet approved
Biologic Classification
Protein Based Therapies
Hormones
Protein Structure
Protein Chemical Formula
C975H1513N267O304S26
Protein Average Weight
22672.9 Da
Sequences
>Alpha chain
APDVQDCPECTLQENPFFSQPGAPILQCMGCCFSRAYPTPLRSKKTMLVQKNVTSESTCC
VAKSYNRVTVMGGFKVENHTACHCSTCYYHKS
>Beta chain
FCIPTEYTMHIERRECAYCLTINTTICAGYCMTRDINGKLFLPKYALSQDVCTYRDFIYR
TVEIPGCPLHVAPYFSYPVALSCKCGKCNTDYSDCIHEAIKTNYCTKPQKSY
Download FASTA Format
Synonyms
  • Recombinant Human Thyroid Stimulating Hormone
  • Recombinant thyrotropin alfa
  • rhTSH
  • rTSH
  • Thyrotropin alfa
  • Thyrotropin alpha
External IDs
  • GX-30
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

For detection of residueal or recurrent thyroid cancer

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Diagnostic agentThyroid cancer••••••••••••••••••••••••••••••••••
Adjunct therapy in treatment ofThyroid cancers••••••••••••••••••••••••••••••••••
Associated Therapies
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Binding of thyrotropin alfa to TSH receptors on normal thyroid epithelial cells or on well-differentiated thyroid cancer tissue stimulates iodine uptake and organification. Thyrogen is an exogenous source of human TSH that offers an additional diagnostic tool in the follow-up of patients with a history of well-differentiated thyroid cancer.

Mechanism of action

Thyrotropin Alfa binds to the thyrotropin receptors found on any residual thyroid cells or tissues. This stimulates radioactive iodine uptake for better radiodiagnostic imaging.

TargetActionsOrganism
AThyrotropin receptor
agonist
Humans
Absorption

Time to peak: Median: 10 hours (range: 3-24 hours) After a single intramuscular injection of 0.9 mg of thyrotropin alfa: Cmax= 116+38mU/L, Tmax=22+8.5 hours. AUC=5088+1728 mU·hr/L.

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

kidney and liver

Half-life

25 ± 10 hours

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

No difference in efficacy and toxicity between adult and geriatric patients. No studies in lactating women, pregnant women and pediatrics. Cautionary administration is advised.

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AcalabrutinibThe therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Acalabrutinib.
AcarboseThyrotropin alfa may decrease the hypoglycemic activities of Acarbose.
AcebutololThe therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Acebutolol.
AcenocoumarolThe risk or severity of bleeding can be increased when Thyrotropin alfa is combined with Acenocoumarol.
AcetohexamideThyrotropin alfa may decrease the hypoglycemic activities of Acetohexamide.
Food Interactions
No interactions found.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
ThyrogenInjection, powder, for solution0.9 mgIntramuscularSanofi B.V.2020-12-23Not applicableEU flag
ThyrogenInjection, powder, lyophilized, for solution0.9 mg/1mLIntramuscularGenzyme Corporation1998-11-30Not applicableUS flag
ThyrogenPowder, for solution0.9 mg / vialIntramuscularSanofi Genzyme, a Division of Sanofi Aventis Canada Inc2002-08-12Not applicableCanada flag
ThyrogenInjection, powder, for solution0.9 mgIntramuscularSanofi B.V.2020-12-23Not applicableEU flag
ThyrogenInjection, powder, for solution; Kit0.9 mg/1mLIntramuscularGenzyme Corporation1998-11-302019-05-30US flag

Categories

ATC Codes
H01AB01 — Thyrotropin alfa
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
AVX3D5A4LM
CAS number
194100-83-9

References

Synthesis Reference

19366632

General References
Not Available
UniProt
P01225
Genbank
M16647
PubChem Substance
46505696
RxNav
4952
ChEMBL
CHEMBL1201533
Therapeutic Targets Database
DAP001248
PharmGKB
PA164746560
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Thyroid-stimulating_hormone
FDA label
Download (2.27 MB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentHypothyroidism / Thyroid Neoplasm1
4CompletedTreatmentThyroid Cancer1
3Active Not RecruitingOtherLow Risk Differentiated Thyroid Cancer1
3Active Not RecruitingTreatmentDifferentiated Thyroid Cancer (DTC)1
3CompletedNot AvailableThyroid Neoplasm1

Pharmacoeconomics

Manufacturers
  • Sanofi aventis us llc
  • Genzyme corp
Packagers
  • Genzyme Inc.
  • Organon Pharmaceuticals
Dosage Forms
FormRouteStrength
Injection, powder, for solutionIntramuscular0.9 mg
Injection, powder, for solution; kitIntramuscular0.9 mg/1mL
Injection, powder, lyophilized, for solutionIntramuscular0.9 mg/1mL
Powder, for solutionIntramuscular0.9 mg / vial
Injection, powder, for solutionIntramuscular
Injection, solutionIntramuscular0.9 mg/1.08ml
Injection, powder, for solutionIntramuscular1.1 mg
Powder0.9 mg/1ml
Injection, powder, lyophilized, for solutionIntramuscular1.1 mg
Prices
Unit descriptionCostUnit
Thyrogen 1.1 mg vial1196.4USD vial
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)Region
US5840566No1998-11-242015-11-24US flag

Properties

State
Liquid
Experimental Properties
PropertyValueSource
melting point (°C)55 °CNot Available
hydrophobicity-0.330Not Available
isoelectric point7.50Not Available

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Details1. Thyrotropin receptor
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Agonist
General Function
Thyroid-stimulating hormone receptor activity
Specific Function
Receptor for thyrothropin. Plays a central role in controlling thyroid cell metabolism. The activity of this receptor is mediated by G proteins which activate adenylate cyclase. Also acts as a rece...
Gene Name
TSHR
Uniprot ID
P16473
Uniprot Name
Thyrotropin receptor
Molecular Weight
86828.965 Da
References
  1. Szkudlinski MW: Recombinant human thyrotropins of the twenty-first century. Expert Opin Pharmacother. 2004 Dec;5(12):2435-40. [Article]
  2. Conway GS: Clinical manifestations of genetic defects affecting gonadotrophins and their receptors. Clin Endocrinol (Oxf). 1996 Dec;45(6):657-63. [Article]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [Article]

Drug created at June 13, 2005 13:24 / Updated at January 02, 2024 23:41